TRAF1 influences the treatment outcomes of drugs like methotrexate and TNF inhibitors used in autoimmune disorders such as rheumatoid arthritis by affecting how these drugs modulate the immune system and inflammatory responses. Genetic variations in TRAF1 can significantly alter the efficacy of these medications because it is central to the pathways that these drugs target, rather than affecting their metabolism or elimination.